Gleevec (imatinib), a new cancer drug for chronic myeloid leukemia

November 2001

Novartis is now marketing Gleevec (imatinib), a new cancer drug for chronic myeloid leukemia.

Gleevec inhibits the proliferation of the abnormal protein that causes rapid and uncontrolled growth of white blood cells.

It specifically targets the cancer cells.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
200+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get quote

Table of Contents

concerns about bioterrorism
SSRIs can prevent heart attacks
diphenhydramine decreases cognitive function in elderly patients
Women's Health NuvaRing, the first contraceptive vaginal ring
Infectious Diseases HIV/AIDS patients taking the new combo product called Trizivir
Infectious Diseases The Lyme vaccine (Lymerix) can now be given in an accelerated dosing schedule
Infectious Diseases Intron A is effective for treating ACUTE hepatitis C
Gastroenterology H. pylori infection increases the risk of gastric cancer
Rheumatoid Arthritis Remicade (infliximab) for rheumatoid arthritis
appropriate use of inhaled steroids for treating persistent asthma
Supplements Vitamin B12 deficiency can often be treated with ORAL supplements
Supplements antioxidants and zinc to slow the progression of age-related macular degeneration (AMD)
Supplements whether glucosamine can cause elevated cholesterol and blood pressure
Anemia Aranesp (darbepoetin alfa), the new longer-acting erythropoietin analog for anemia
Hematology & Oncology Gleevec (imatinib), a new cancer drug for chronic myeloid leukemia
Neurology & Pain big push to avoid using Demerol (meperidine)